Mechanism‐based treatment of cancer with immune checkpoint inhibitor therapies
Yara Abdou, Manu Pandey, Maithreyi Sarma, Shrunjal Shah, Jeffrey Baron, Marc S. Ernstoff
Abstract
cytolytic T cell activity. Antagonistic and agonistic antibodies engaging these molecules have demonstrated profound impact on immune activation and have entered clinical use for the treatment of a variety of diseases. Over the past decade, antagonistic antibodies known as immune checkpoint inhibitors have become a new pillar of cancer treatment and have reshaped the therapeutic landscape in oncology. These agents differ in their mechanism of action and toxicity profiles compared to more traditional systemic cancer treatments such as chemo- and targeted therapies. This article reviews the pharmacology of this new class of agents.
Topics & Concepts
Immune systemCancerImmune checkpointMechanism (biology)AntibodyMedicineCD8Mechanism of actionPillarImmunotherapyCancer researchImmunologyBiologyInternal medicineIn vitroBiochemistryStructural engineeringEpistemologyPhilosophyEngineeringCancer Immunotherapy and BiomarkersCAR-T cell therapy researchImmune Cell Function and Interaction